Use of periplocymarin in the preparation of a MAPK14 phosphorylation inhibitor

By developing Periplocymarin as a phosphorylation inhibitor of MAPK14, the problems of tumor cell heterogeneity and drug resistance in existing lung cancer treatments have been solved, enabling the development of efficient and safe anti-lung cancer drugs and providing new research and development tools and a basis for clinical application.

CN122097397APending Publication Date: 2026-05-29AFFILIATED HOSPITAL OF NANTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
AFFILIATED HOSPITAL OF NANTONG UNIV
Filing Date
2026-02-13
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

Current treatments for lung cancer often result in poor patient prognosis due to the high heterogeneity and drug resistance of tumor cells. There is an urgent need to develop new, highly effective, and safe anti-tumor drugs. The role of Periplocymarin in lung cancer remains unclear.

Method used

Periplocymarin was used as a phosphorylation inhibitor of MAPK14. By screening and evaluating its inhibitory effect on the phosphorylation level of MAPK14 protein, MAPK14 signaling pathway reagents were prepared for the research and development of anti-lung cancer drugs, including injections, oral formulations, inhalers, or topical formulations.

Benefits of technology

The anti-tumor mechanism of Periplocymarin has been clarified, which significantly inhibits the proliferation and metastasis of lung cancer cells, has good in vivo anti-tumor activity, low toxicity and side effects, and is suitable for long-term use. It provides a new drug development tool and promotes clinical translation and combination drug research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122097397A_ABST
    Figure CN122097397A_ABST
Patent Text Reader

Abstract

The application discloses a use of Periplocymarin in preparation of a MAPK14 phosphorylation inhibitor, and belongs to the technical field of biological medicines. The application discloses for the first time that Periplocymarin can directly target MAPK14 protein and inhibit phosphorylation of the MAPK14 protein, thereby effectively inhibiting proliferation and migration of NSCLC cells and inducing cell apoptosis. The application verifies the above-mentioned mechanism of action through protein thermal stability analysis, network pharmacology, microscale thermophoresis (MST) technology, Western Blot and gene interference experiment system. The application further shows through PDO model, nude mouse subcutaneous transplantation tumor model and PDX model experiments that Periplocymarin can significantly inhibit tumor growth and has good safety. Therefore, the application has a significant application prospect and popularization value.
Need to check novelty before this filing date? Find Prior Art